

Experiment Number: 55301-03
Test Type: 90-DAY
Species/Strain: Rat/WISTAR OUTBR

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Test Compound: Pyridine
CAS Number: 110-86-1

Date Report Requested: 10/21/2014
Time Report Requested: 15:45:39
First Dose M/F: NA / NA
Lab: TSI MASON

C Number: C55301B
Lock Date: Not Entered.
Cage Range: All
Date Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: All
Study Gender: Male
PWG Approval Date: NONE

Experiment Number: 55301-03
 Test Type: 90-DAY
 Species/Strain: Rat/WISTAR OUTBR

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
 AVERAGE SEVERITY GRADES[b]**
 Test Compound: Pyridine
 CAS Number: 110-86-1

Date Report Requested: 10/21/2014
 Time Report Requested: 15:45:39
 First Dose M/F: NA / NA
 Lab: TSI MASON

WISTAR OUTBR Rat MALE	0 PPM	50 PPM	100 PPM	250 PPM	500 PPM	1000 PPM
Disposition Summary						
Animals Initially In Study	10	10	10	10	10	10
Early Deaths						
Natural Death					1	
Survivors						
Terminal Sacrifice	10	10	10	10	9	10
Animals Examined Microscopically	10	10	10	10	9	10
ALIMENTARY SYSTEM						
Esophagus	(10)	(0)	(0)	(0)	(0)	(9)
Intestine Large, Cecum	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Large, Colon	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Large, Rectum	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Small, Duodenum	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Small, Ileum	(10)	(0)	(0)	(0)	(0)	(10)
Intestine Small, Jejunum	(10)	(0)	(0)	(0)	(0)	(10)
Liver	(10)	(10)	(10)	(10)	(9)	(10)
Centrilobular, Degeneration					9 [1.7]	9 [1.4]
Centrilobular, Necrosis					1 [1.0]	1 [2.0]
Clear Cell Focus			1	1 [1.0]		1
Hypertrophy					9 [1.0]	10 [1.0]
Inflammation, Chronic				2 [1.0]	9 [1.7]	9 [2.2]
Necrosis, Focal		1 [1.0]	2 [1.0]			
Pigmentation					9 [1.0]	9 [1.3]
Regeneration						1 [2.0]
Pancreas	(10)	(0)	(0)	(0)	(0)	(10)
Salivary Glands	(10)	(0)	(0)	(0)	(0)	(10)
Stomach, Forestomach	(10)	(0)	(0)	(0)	(0)	(10)
Stomach, Glandular	(10)	(0)	(0)	(0)	(0)	(10)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 55301-03

Test Type: 90-DAY

Species/Strain: Rat/WISTAR OUTBR

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

Test Compound: Pyridine

CAS Number: 110-86-1

Date Report Requested: 10/21/2014

Time Report Requested: 15:45:39

First Dose M/F: NA / NA

Lab: TSI MASON

WISTAR OUTBR Rat MALE	0 PPM	50 PPM	100 PPM	250 PPM	500 PPM	1000 PPM
Inflammation, Acute	1 [1.0]					1 [1.0]
CARDIOVASCULAR SYSTEM						
Heart	(10)	(0)	(0)	(0)	(9)	(10)
Cardiomyopathy	5 [1.2]				8 [1.0]	2 [1.0]
ENDOCRINE SYSTEM						
Adrenal Gland, Cortex	(10)	(0)	(0)	(0)	(0)	(10)
Adrenal Gland, Medulla	(10)	(0)	(0)	(0)	(0)	(10)
Islets, Pancreatic	(10)	(0)	(0)	(0)	(0)	(10)
Parathyroid Gland	(9)	(0)	(0)	(0)	(0)	(7)
Pituitary Gland	(10)	(0)	(0)	(0)	(0)	(10)
Thyroid Gland	(10)	(0)	(0)	(0)	(0)	(10)
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
Epididymis	(9)	(0)	(0)	(0)	(0)	(10)
Preputial Gland	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation, Chronic Active	1 [1.0]					1 [2.0]
Prostate	(10)	(0)	(0)	(0)	(0)	(10)
Seminal Vesicle	(10)	(0)	(0)	(0)	(0)	(10)
Testes	(10)	(0)	(0)	(0)	(1)	(10)
Edema					1 [1.0]	
Seminif Tub, Giant Cell	1 [2.0]					
HEMATOPOIETIC SYSTEM						
Bone Marrow	(10)	(0)	(0)	(0)	(0)	(10)
Lymph Node	(1)	(0)	(0)	(0)	(0)	(0)
Lumbar, Hyperplasia, Lymphoid	1 [2.0]					
Lymph Node, Mandibular	(10)	(1)	(1)	(1)	(0)	(10)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 55301-03
 Test Type: 90-DAY
 Species/Strain: Rat/WISTAR OUTBR

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
 AVERAGE SEVERITY GRADES[b]**
 Test Compound: Pyridine
 CAS Number: 110-86-1

Date Report Requested: 10/21/2014
 Time Report Requested: 15:45:39
 First Dose M/F: NA / NA
 Lab: TSI MASON

WISTAR OUTBR Rat MALE	0 PPM	50 PPM	100 PPM	250 PPM	500 PPM	1000 PPM
Angiectasis				1 [2.0]		
Hyperplasia, Lymphoid	1 [2.0]	1 [2.0]	1 [3.0]			1 [2.0]
Lymph Node, Mesenteric	(10)	(0)	(0)	(0)	(0)	(10)
Hyperplasia, Lymphoid	1 [2.0]					
Spleen	(10)	(0)	(0)	(0)	(0)	(10)
Thymus	(10)	(0)	(0)	(0)	(0)	(10)
INTEGUMENTARY SYSTEM						
Mammary Gland	(9)	(0)	(0)	(0)	(0)	(9)
Skin	(10)	(1)	(0)	(0)	(0)	(10)
MUSCULOSKELETAL SYSTEM						
Bone	(10)	(0)	(0)	(0)	(0)	(10)
NERVOUS SYSTEM						
Brain	(10)	(0)	(0)	(0)	(0)	(10)
RESPIRATORY SYSTEM						
Lung	(10)	(0)	(0)	(0)	(0)	(10)
Edema						2 [1.0]
Hemorrhage	2 [1.0]					1 [1.0]
Infiltration Cellular, Histiocyte	3 [1.0]					1 [1.0]
Nose	(10)	(0)	(0)	(0)	(0)	(10)
Inflammation, Acute	1 [1.0]					
Trachea	(10)	(0)	(0)	(0)	(0)	(10)
SPECIAL SENSES SYSTEM						
None						
URINARY SYSTEM						
Kidney	(10)	(10)	(10)	(10)	(9)	(10)
Casts	3 [1.0]	3 [1.0]	4 [1.0]	4 [1.5]	4 [1.0]	5 [1.0]
Casts Granular						1 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 55301-03
Test Type: 90-DAY
Species/Strain: Rat/WISTAR OUTBR

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH
AVERAGE SEVERITY GRADES[b]**

Test Compound: Pyridine
CAS Number: 110-86-1

Date Report Requested: 10/21/2014
Time Report Requested: 15:45:39
First Dose M/F: NA / NA
Lab: TSI MASON

WISTAR OUTBR Rat MALE	0 PPM	50 PPM	100 PPM	250 PPM	500 PPM	1000 PPM
Hydronephrosis	2 [1.5]	2 [1.0]				
Inflammation, Chronic		1 [1.0]	1 [2.0]			2 [1.0]
Mineralization	7 [1.0]	5 [1.2]	4 [1.0]	8 [1.3]	8 [1.0]	10 [1.0]
Renal Tubule, Degeneration, Hyaline	2 [1.0]			2 [1.0]	3 [1.0]	6 [1.0]
Renal Tubule, Regeneration	5 [1.0]	6 [1.0]	5 [1.0]	9 [1.0]	7 [1.0]	8 [1.1]
Urinary Bladder	(10)	(0)	(0)	(2)	(0)	(10)
Calculus Gross Observation				1		1
Calculus Micro Observation Only				1		1
Concretion				1 [2.0]		
Dilatation						1 [2.0]

** END OF REPORT **

a - Number of animals examined microscopically at site and number of animals with lesion
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)